Skip to main content
SpringerLink
Log in

Infections in Patients with Leukemia and Lymphoma

  • Chapter
  • First Online:
Infectious Complications in Cancer Patients

Part of the book series: Cancer Treatment and Research ((CTAR,volume 161))

Abstract

Infectious complications remain a significant issue in the care of patients with hematologic malignancies. Inherent immune defects related to the primary disease process are present in patients with disorders such as chronic lymphocytic leukemia, multiple myeloma, hairy cell leukemia, and Hodgkin lymphoma. Therapy-related immunosuppression is also commonplace in these patients. This includes not only treatment-related neutropenia, but also defects in cell-mediated immunity, such as those that occur with purine analog therapy. In this chapter, we will review the pathogenesis of infection in these disorders, as well as the spectrum of infectious complications seen and suggested strategies for the prevention of infection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wadhwa PD, Morrison VA (2006) Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33:240–249

    PubMed  CAS  Google Scholar 

  2. Morrison VA (2007) Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology 332–338

    Google Scholar 

  3. Sinisalo M, Aittoniemi J, Koski T et al (2004) Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. Leuk Lymphoma 45:2451–2454

    PubMed  CAS  Google Scholar 

  4. Francis S, Karanth M, Pratt G, Starczynski J, Hooper L, Fegan C, Pepper C, Valcarcel D, Milligan DW, Delgado J (2006) The status on immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107:1023–1033

    PubMed  CAS  Google Scholar 

  5. Morrison VA, Hibbs JR, Janoff EN (1996) Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma. Blood 88:240a

    Google Scholar 

  6. Oshima K, Kanda Y, Nannya Y et al (2001) Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 67:1–5

    PubMed  CAS  Google Scholar 

  7. Jacobson DR, Zolla-Pazner S (1986) Immunosuppression and infection in multiple myeloma. Semin Oncol 282–290

    Google Scholar 

  8. Fahey JL, Scoggins R, Utz JP et al (1963) Infection, antibody response and gamma globulin concentrations in multiple myeloma and macroglobulinemia. Am J Med 35:698–707

    PubMed  CAS  Google Scholar 

  9. Broder S, Humphrey R, Durm M et al (1975) Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. N Engl J Med 293:887–892

    PubMed  CAS  Google Scholar 

  10. Morell A, Terry WD, Waldmann TA (1970) Metabolic properties of IgG subclasses in man. J Clin Invest 49:673–680

    PubMed Central  PubMed  CAS  Google Scholar 

  11. Marks J (1953) Antibody formation in myelomatosis. J Clin Pathol 6:62–63

    PubMed Central  PubMed  CAS  Google Scholar 

  12. Lawson HA, Stuart CA, Paull AM et al (1955) Observations on the antibody content of the blood in patients with multiple myeloma. N Engl J Med 252:13–18

    PubMed  CAS  Google Scholar 

  13. Heath RB, Hamilton F, Malpas JS (1964) Production of antibodies against viruses in leukaemia and related diseases. Br J Haematol 10:365–370

    PubMed  CAS  Google Scholar 

  14. Fink PC, Galanos C (1985) Serum anti-lipid A antibodies in multiple myeloma and Waldenstrom’s macroglobulinaemia. Immunobiology 169:1–10

    PubMed  CAS  Google Scholar 

  15. Stoll C, Schedel I, Peest D et al (1985) Serum antibodies against common antigens of bacterial lipopolysaccharides in healthy adults and patients with multiple myeloma. Infection 13:115–119

    PubMed  CAS  Google Scholar 

  16. Van Camp B, Reynaert PH, Broodtaerts L (1981) Studies on the origin of the precursor cells in multiple myeloma, Waldenstrom’s macroglobulinemia and benign monoclonal gammopathy. I. Cytoplasmic isotype and idiotype distribution in peripheral blood and bone marrow. Clin Exp Imunol 44:82–89

    Google Scholar 

  17. Dillman RO, Royston I, Meserve BL et al (1981) Alterations of peripheral blood B-lymphocyte populations in plasma cell disorders. Cancer 48:2211–2217

    PubMed  CAS  Google Scholar 

  18. King MA, Wells JV (1981) Cell-bound immunoglobulin on peripheral blood mononuclear cells of patients with myeloma. Clin Exp Immunol 45:522–556

    Google Scholar 

  19. Bast EJEG, Van Camp B, Reynaert P et al (1982) Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol 47:677–682

    PubMed Central  PubMed  CAS  Google Scholar 

  20. Pilarski LM, Mant MJ, Ruether BA et al (1984) Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients. J Clin Invest 74:1301–1306

    PubMed Central  PubMed  CAS  Google Scholar 

  21. Lindstrom FD, Hardy WR, Eberle BJ et al (1973) Multiple myeloma and benign monoclonal gammopathy: differentiation by immunofluorescence of lymphocytes. Ann Intern Med 78:837–844

    PubMed  CAS  Google Scholar 

  22. Abdou NI, Abdou NL (1975) The monoclonal nature of lymphocytes in multiple myeloma. An Intern Med 83:42–45

    CAS  Google Scholar 

  23. Chen Y, Bhoopalam N, Yakulis BS et al (1975) Changes in lymphocyte surface immunoglobulins in myeloma and the effect of an RNA-containing plasma factor. Ann Intern Med 83:625–631

    PubMed  CAS  Google Scholar 

  24. Glenchur H, Zinnerman HH, Hall WH (1959) A review of fifty-one cases of multiple myeloma. Arch Intern Med 103:173–183

    CAS  Google Scholar 

  25. Cone L, Uhr JW (1964) Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma. J Clin Invest 43:2241–2248

    PubMed Central  PubMed  CAS  Google Scholar 

  26. Zinneman HH, Hall WH (1954) Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Ann Intern Med 41:1152–1163

    PubMed  CAS  Google Scholar 

  27. Larson DL, Tomlinson LJ (1952) Quantitative antibody studies in man. II. The relation of the level of serum proteins to antibody production. J Lab Clin Med 39:129–134

    PubMed  CAS  Google Scholar 

  28. Lazarus HM, Lederman M, Lubin A et al (1980) Pneumococcal vaccination: the response of patients with multiple myeloma. Am J Med 69:419–423

    PubMed  CAS  Google Scholar 

  29. Schidt RA, Rubin RR, Schiffman G et al (1981) polyvalent pneumococcal immunization of patients with plasma cell dyscrasias. Cancer 48:1377–1380

    Google Scholar 

  30. Birgens HS, Espersen F, Hertz JB et al (1983) Antibody response to pneumococcal vaccination in patients with myelomatosis. Scand J Haematol 30:324–330

    PubMed  CAS  Google Scholar 

  31. Cheson BD, Plas PR, Rothstein G (1980) Defective opsonization in multiple myeloma. Blood 55:602–606

    PubMed  CAS  Google Scholar 

  32. Kraut EH, Sagone AL (1981) Alternate pathway of complement in multiple myeloma. Am J Hematol 11:335–345

    PubMed  CAS  Google Scholar 

  33. Cheson BD, Walker HS, Heath ME et al (1984) Defective binding of the third component of complement (C3) to Streptococcus pneumoniae in multiple myeloma. Blood 63:949–957

    PubMed  CAS  Google Scholar 

  34. MacGregor RR, Negendank WG, Schreiber AD (1978) Impaired granulocyte adherence in multiple myeloma: relationship to complement system, granulocyte delivery, and infection. Blood 51:591–599

    PubMed  CAS  Google Scholar 

  35. Spitler LE, Spath P, Petz L et al (1975) Phagocytes and C4 in paraproteinaemia. Br J Haematol 29:279–292

    PubMed  CAS  Google Scholar 

  36. Penny R, Galton DAG (1966) Studies on neutrophil function II. Pathological aspects. Br J Haematol 12:633–645

    PubMed  CAS  Google Scholar 

  37. Hopen G, Glette J, Halstensen A et al (1983) Granulocyte function in malignant monoclonal gammopathy. Scand J Haematol 31:133–143

    PubMed  CAS  Google Scholar 

  38. Ziegler JB, Hansen PJ, Penny R (1975) Leucocyte function in paraproteinemia. Aust NZ J Med 5:39–43

    CAS  Google Scholar 

  39. Naess A, Hopen G, Solberg CO (1984) Decrease of Fcγ and C3b receptor-bearing granulocytes and of T lymphocytes in myelomatosis. Scand J Haematol 33:83–90

    PubMed  CAS  Google Scholar 

  40. Dammacco F, Miglietta A, Ventura MT et al (1982) Defective monocyte chemotactic responsiveness in patients with multiple myeloma and benign monoclonal gammopathy. Clin Exp Immunol 47:481–486

    PubMed Central  PubMed  CAS  Google Scholar 

  41. Blom J, Nielsen H, Larsen SO et al (1984) A study of certain functional parameters of monocytes from patients with multiple myeloma: comparison with monocytes from healthy individuals. Scand J Haematol 33:425–431

    PubMed  CAS  Google Scholar 

  42. Fahey JL, Humphrey JH (1962) Effect of transplantable plasma-cell tumors on antibody response in mice. Immunology 5:110–115

    PubMed Central  PubMed  CAS  Google Scholar 

  43. Havas HF, Schiffman G (1978) The effect of an IgM plasmacytoma (TEPC-183) on the primary immune response of BALB/c mice. Immunology 34:1–8

    PubMed Central  PubMed  CAS  Google Scholar 

  44. Smith F, Grenan ZMM, Owens J (1960) Effect of a transplanted plasma-cell tumor on antibody formation. J Natl Cancer Inst 25:803–812

    Google Scholar 

  45. Zolla S (1972) The effect of plasmacytomas on the immune response of mice. J Immunol 108:1039–1048

    PubMed  CAS  Google Scholar 

  46. Hirano S, Imamura Y, Takaku F et al (1968) Immune response in mice with plasma-cell tumor (X5563) assayed by agar plaque technique. Blood 31:252–257

    PubMed  CAS  Google Scholar 

  47. Zolla S, Naor D, Tanapatchaiyapong P (1974) Cellular basis of immunodepression in mice with plasmacytomas. J Immunol 112:2068–2076

    PubMed  CAS  Google Scholar 

  48. Ullrich S, Zolla-Pazner S (1982) Immunoregulatory circuits in myeloma. Clin Haematol 11:87–111

    PubMed  CAS  Google Scholar 

  49. Tanapatchaiyapong P, Zolla S (1974) Humoral immunosuppressive substance in mice bearing plasmacytomas. Science 186:748–750

    PubMed  CAS  Google Scholar 

  50. Kolb J-P, Arrian S, Zolla-Pazner S (1977) Suppression of the humoral immune response by plasmacytomas: mediation by adherent mononuclear cells. J Immunol 118:702–709

    PubMed  CAS  Google Scholar 

  51. Kennard J, Zolla-Pazner S (1980) Origin and function of suppressor macrophages in myeloma. J Immunol 124:268–273

    PubMed  CAS  Google Scholar 

  52. Krakauer RS, Strober W, Waldmann TA (1977) Hypogammaglobulinemia in experimental myeloma: the role of suppressor factors from mononuclear phagocytes. J Immunol 118:1385–1390

    PubMed  CAS  Google Scholar 

  53. Katzmann JA (1978) Myeloma-induced immunosuppression: a multistep mechanism. J Immunol 121:1405–1409

    PubMed  CAS  Google Scholar 

  54. Hamburger AW (1980) Inhibition of B-lymphocyte clonal proliferation by spleen cells from plasmacytoma-bearing mice. J Natl Cancer Inst 65:1337–1343

    PubMed  CAS  Google Scholar 

  55. Berman JE, Zolla-Pazner S (1985) Control of B cell proliferation: inhibition of responses to B cell mitogens induced by plasma cell tumors. J Immunol 134:2872–2878

    PubMed  CAS  Google Scholar 

  56. Hoover RG, Dieckgraefe BK, Lake J et al (1982) Lymphocyte surface membrane immunoglobulin in myeloma. III. IgA plasmacytomas induce large numbers of circulating, adult thymectomy-sensitive, θ+, Lyt-1 − 2+ lymphocytes with IgA-Fc receptors. J Immunol 129:2329–2331

    PubMed  CAS  Google Scholar 

  57. Hoover RG, Lynch RG (1983) Isotype-specific suppression of IgA: suppression of IgA responses in BALB/c mice by Tα cells. J Immunol 130:521–523

    PubMed  CAS  Google Scholar 

  58. Hoover RG, Dieckgraefe BK, Lynch RG (1981) T cells with Fc receptors for IgA: induction of T cells in vivo and in vitro by purified IgA. J Immunol 127:1560–1563

    PubMed  CAS  Google Scholar 

  59. Mather A, Lynch RG (1986) Increased Tγ and Tμ cells in BALB/c mice with Ig G and IgM plasmacytomas and hybridomas. J Immunol 136:521–525

    Google Scholar 

  60. Muller S, Hoover RG (1985) T cells with Fc receptors in myeloma: suppression of growth and secretion of MOPC-315 by Tα cells. J Immunol 134:644–647

    PubMed  CAS  Google Scholar 

  61. Jones SV, McFarlane H (1975) T and B cells in myelomatosis. Br J Haematol 31:545–552

    PubMed  CAS  Google Scholar 

  62. Sato I, Abo T, Onodera S et al (1978) Detection of monoclonal B lymphocytes in multiple myeloma by immunofluorescence tests of surface immunoglobulins. Scand J Haematol 21:433–444

    PubMed  CAS  Google Scholar 

  63. Kubagawa W, Vogler LB, Capra JD et al (1979) Studies on the clonal origin of multiple myeloma: use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med 150:792–807

    PubMed  CAS  Google Scholar 

  64. Schedel I, Peest D, Stunkel K et al (1980) Idiotype-bearing peripheral blood lymphocytes in human multiple myeloma and Waldenstrom’s macroglobulinemia. Scand J Immunol 11:437–444

    PubMed  CAS  Google Scholar 

  65. Carmagnola AL., Boccadoro M, Massaia M et al (1983) The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. Clin Exp Immunol 51:173–177

    Google Scholar 

  66. Leonard RCF, MacLennan CM, Smart Y et al (1979) Light chain isotype-associated suppression of normal plasma cell number in patients with multiple myeloma. Int J Cancer 24:385–393

    PubMed  CAS  Google Scholar 

  67. Werne A, Joshua DE, Kronenberg H (1984) Light chain isotype associated suppression of surface immunoglobulin expression on peripheral blood lymphocytes in myeloma during plateau phase. Br J Haematol 58:483–489

    Google Scholar 

  68. Kraut E (2003) Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Pract Res Clin Haematol 16(1):33–40

    PubMed  Google Scholar 

  69. Offerman MK, Golomb H (1984) Hairy cell leukemia. Curr Probl Cancer 8(7):1–39

    Google Scholar 

  70. Golomb H, Hadad L (1984) Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 16:393–401

    PubMed  CAS  Google Scholar 

  71. Stewart DJ, Gp B (1981) Infections in hairy cell leukemia. Cancer 15:801–805

    Google Scholar 

  72. Mackowiak P, Demian S, Sutker W et al (1980) Infections in hairy cell leukemia, clinical evidence of a pronounced defect in cell-mediated immunity. Am J Med 68:718–723

    PubMed  CAS  Google Scholar 

  73. Bouza E, Burgaleta C, Golde D (1978) Infections in hairy-cell leukemia. Blood 51(5):851–859

    PubMed  CAS  Google Scholar 

  74. Kraut EH, Grever MR, Bourouncle B (1994) Long term follow-up of patients with hairy cell leukemia after treatment with 2″ deoxycoformycin. Blood 84:4061–4063

    PubMed  CAS  Google Scholar 

  75. Goodman G, Burian C, Koziol J et al (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 25(5):891–896

    Google Scholar 

  76. Child JA, Cawley JC, Martin S (1979) Microbicidal function of the neutrophils in hairy cell leukemia. Acta Haematol 62:191–198

    PubMed  CAS  Google Scholar 

  77. Yam LT, Chaudhry AA, Janckila AJ (1977) Impaired marrow granulocyte reserve and leukocyte mobilization in leukemic reticuloendotheliosis. Ann Intern Med 87:444–446

    PubMed  CAS  Google Scholar 

  78. Kjeldsberg CR (1978) Leukocyte mobilization in leukemic reticuloendotheliosis (letter). Ann Intern Med 88:268–269

    PubMed  CAS  Google Scholar 

  79. Seshadri R, Brown E, Zipursky A (1976) Leukemic reticuloendotheliosis: a failure of monocyte production. New Engl J Med 295:181–184

    PubMed  CAS  Google Scholar 

  80. Ruco LP, Procopio A, Maccanallini V (1983) Severe deficiency of natural killer cell activity in the peripheral blood of patients with hairy cell leukemia. Blood 61:1131–1137

    Google Scholar 

  81. Bourguin-Pionquet A, Rouard H, Roudot-Thoraval F (2002) Severe decrease in peripheral blood dendritic cells in hairy cell leukemia. Brit J Haematol 116:595–597

    Google Scholar 

  82. Damaj G, Kuhnowski F, Marolleau JP et al (2009) Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol 83:246–250

    PubMed  Google Scholar 

  83. Golomb H, Hanauer S (1981) Infectious complications associated with hairy cell leukemia. J Infect Dis 143:639–643

    PubMed  CAS  Google Scholar 

  84. Berliner N (1990) T gamma lymphocytosis and T cell chronic leukemias. Hematol Oncol Clin North Am 4:473–487

    PubMed  CAS  Google Scholar 

  85. Mohan SR, Maciejewski JP (2009) Diagnosis and therapy of neutropenia in large granular lymphocytic leukemia. Curr Opin Hematol 16:27–34

    PubMed  CAS  Google Scholar 

  86. Loughran TP, Starkebaum G (1987) Large granular lymphocytic leukemia: report of 38 cases and review of the literature. Medicine 66:397–405

    PubMed  Google Scholar 

  87. Casazza AR, Duvall CP, Carbone PP (1966) Summary of infectious complications occurring in patients with Hodgkin’s disease. Cancer Res 26:1290–1296

    PubMed  CAS  Google Scholar 

  88. Colby TV, Richard TH, Roger AW (1981) Hodgkin’s disease and autopsy. Cancer 47:1852–1862

    PubMed  CAS  Google Scholar 

  89. Romagnani S, Ferrini PLR, Ricci M (1985) The immune derangement in Hodgkin’s disease. Semin Hematol 22:41–55

    PubMed  CAS  Google Scholar 

  90. Baldwin RW (1972) Immunological aspects of Hodgkin’s disease. Proc R Soc Med 65:1113

    PubMed Central  PubMed  CAS  Google Scholar 

  91. Gupta S (1981) Immunodeficiencies in Hodgkin’s disease. Part I: T cell-mediated immunity. Clin Bull 11:58–65

    PubMed  CAS  Google Scholar 

  92. Bjorkholm M, Wedelin C, Holm G, Ogenstad S, Johansson B, Mellstedt H (1982) Immune status of untreated patients with Hodgkin’s disease and prognosis. Cancer Treat Rep 66:701–709

    PubMed  CAS  Google Scholar 

  93. Bjorkholm M (1978) Immunodeficiency in Hodgkin’s disease and its relation to prognosis. Scand J Haematol 33(Suppl):7–74

    Google Scholar 

  94. Holm G, Mellstedt H, Bjorkholm M, Johansson B, Killander D, Sundblad R, Soderberg G (1976) Lymphocyte abnormalities in untreated patients with Hodgkin’s disease. Cancer 37:751–762

    PubMed  CAS  Google Scholar 

  95. Hunter CP, Tannenbaum H, Churchill WH, Moloney WC, Schur PH (1997) Immunologic abnormalities in patients with malignant lymphoproliferative diseases. J Natl Cancer Inst 58:11185–11190

    Google Scholar 

  96. Franzke A, Koenecke C, Geffers R, Piao W, Hunger JK, Ganser A, Buer J (2006) Classical Hodgkin lymphoma: molecular evidence for specific alterations in circulating T lymphocytes. Tumour Biol 27:329–333

    PubMed  CAS  Google Scholar 

  97. Levy R, Kaplan HS (1974) Impaired lymphocyte function in untreated Hodgkin’s disease. N Engl J Med 290:181–186

    PubMed  CAS  Google Scholar 

  98. Graze PR, Perlin E, Royston I (1976) In vitro lymphocyte dysfunction in Hodgkin’s disease. J Natl Cancer Inst 56:239–243

    PubMed  CAS  Google Scholar 

  99. Hillinger SM, Herzig GP (1978) Impaired cell-mediated immunity in Hodgkin’s disease mediated by suppressor lymphocytes and monocytes. J Clin Invest 61:1620–1627

    PubMed Central  PubMed  CAS  Google Scholar 

  100. Twomey JJ, Laughter AH, Rice L, Ford R (1980) Spectrum of immunodeficiencies with Hodgkin’s disease. J Clin Invest 66:629–637

    PubMed Central  PubMed  CAS  Google Scholar 

  101. Aisenberg AC (1964) Hodgkin’s disease: prognosis, treatment, and etiologic and immunologic considerations. New Engl J Med 270:508–514, 565–570, 617–622

    Google Scholar 

  102. Aisenberg AC, Leskowitz S (1963) Antibody formation in Hodgkin’s disease. New Engl J Med 268:1269–1272

    Google Scholar 

  103. Kelly WD, Lamb DL, Varco RL, Good RA (1960) An investigation of Hodgkin’s disease with respect to the problem of homotransplantation. An NY Acad Sci 87:187–202

    CAS  Google Scholar 

  104. Brown RS, Haynes RA, Foley HT (1967) Hodgkin’s disease: immunological, clinical, and histological features of 50 untreated patients. Ann Intern Med 67:291–300

    PubMed  CAS  Google Scholar 

  105. Eltringham JR, Kaplan HS (1973) Impaired delayed hypersensitivity responses in 154 patients with untreated Hodgkin’s disease. Natl Cancer Inst Monogr 36:107–115

    PubMed  CAS  Google Scholar 

  106. Del Giacco GS, Manconi PE, Tognella S, Mantovani G, Grifoni V (1972) Delayed hypersensitivity in Hodgkin’s disease. Boll Soc Ital Biol Sper 48:377–381

    PubMed  Google Scholar 

  107. Winkelstein A, Mikulla JM, Sartiano GP, Ellis LD (1974) Cellular immunity in Hodgkin’s disease: comparison of cutaneous reactivity and lymphoproliferative responses to phytohemagglutinin. Cancer 34:549–553

    PubMed  CAS  Google Scholar 

  108. Shiftan TA, Caviles AP Jr, Mendelsohn J (1978) Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin’s disease. Clin Exp Immunol 32:144–152

    PubMed Central  PubMed  CAS  Google Scholar 

  109. Ford RJ, Tsao J, Kouttab NM, Sahasrabuddhe CG, Mehta SR (1984) Association of an interleukin abnormality with the T cell defect in Hodgkin’s disease. Blood 64:386–392

    PubMed  CAS  Google Scholar 

  110. Young RC, Corder MP, Haynes HA (1972) Delayed hypersensitivity in Hodgkin’s disease: a study of 103 untreated patients. Amer J Med 52:63–72

    Google Scholar 

  111. Aisenberg AC (1973) Malignant lymphoma. New Engl J Med 288:883–889

    PubMed  CAS  Google Scholar 

  112. Young RC, Corder MP, Berard CW, DeVita VT (1973) Immune alterations in Hodgkin’s disease: effect of delayed hypersensitivity and lymphocyte transformation on course and survival. Arch Intern Med 131:446–454

    PubMed  CAS  Google Scholar 

  113. Schier WW, Roth A, Ostroff G, Schrift MH (1956) Hodgkin’s disease and immunity. Am J Med 20:94–99

    PubMed  CAS  Google Scholar 

  114. Jackson SM, Garrett JV, Craig AW (1970) Lymphocyte transformation changes during the clinical course of Hodgkin’s disease. Cancer 25:843–850

    PubMed  CAS  Google Scholar 

  115. Amlot PL, Slaney JM, Williams BD (1976) Circulating immune complexes and symptoms in Hodgkin’s disease. Lancet 1:449–451

    PubMed  CAS  Google Scholar 

  116. Brown CA, Hall CL, long J (1978) Circulating immune complexes in Hodgkin’s disease. Am J Med 64:289–294

    Google Scholar 

  117. Heier HE, Klepp R, Gundersen S (1977) Blood B and T lymphocytes and in vitro cellular immune reactivity in untreated human malignant lymphomas and other malignant tumors. Scand J Haematol 18:137–148

    PubMed  CAS  Google Scholar 

  118. Van Rijswijk RE, Sybesma JP, Kater L (1983) A prospective study of the changes in the immune status before, during, and after multiple-agent chemotherapy for Hodgkin’s disease. Cancer 51:637–644

    PubMed  Google Scholar 

  119. Bjorkholm M, Holm G, Mellstedt H (1977) Immunologic profile of patients with cured Hodgkin’s disease. Scand J Haematol 18:361–368

    PubMed  CAS  Google Scholar 

  120. Hancock BW, Bruce L, Dunsmore IR, Ward AM, Richmond J (1977) Follow-up studies on the immune status of patients with Hodgkin’s disease after splenectomy and treatment, in relapse and remission. Br J Cancer 36:347–354

    PubMed Central  PubMed  CAS  Google Scholar 

  121. Hancock BW, Bruce L, Whitham MD, Dunsmore IR, Ward AM, Richmond J (1982) Immunity in Hodgkin’s disease: status after 5 years’ remission. Br J Cancer 46:593–600

    PubMed Central  PubMed  CAS  Google Scholar 

  122. Fisher RI, DeVita VT, Bostick F, Vanhaelen C, Howser DM, Hubbard SM, Young RC (1980) Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin’s disease. Ann Intern Med 92:595–599

    PubMed  CAS  Google Scholar 

  123. Skovmann-Sorensen O, Schroder H, Moller-Larsen A, Haahr S (1981) Cellular and humoral immunity in Hodgkin’s disease. I. Patients in continuous long-term remission. Scand J Haematol 27:171–180

    PubMed  CAS  Google Scholar 

  124. Pomeroy C, Oken MM, Rydell RE, Filice GA (1991) Infection in the myelodysplastic syndromes. Am J Med 90:338–344

    PubMed  CAS  Google Scholar 

  125. Martin S, Baldock SC, Ghoneim A, Child JA (1983) Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. J Clin Pathol 36:1120–1128

    PubMed Central  PubMed  CAS  Google Scholar 

  126. Cech P, Markert M, Perrin LH (1983) Partial myeloperoxidase deficiency in preleukemia. Blut 47:21–30

    PubMed  CAS  Google Scholar 

  127. Scott CS, Cahill A, Bynoe AG, Aihley MJ, Hough D, Roberts BE (1983) Esterase cytochemistry in primary myelodysplastic syndrome and megaloblastic anemia. Br J Haematol 55:411–418

    PubMed  CAS  Google Scholar 

  128. Boogaerts MA, Nelissen V, Roelant C, Goosens W (1983) Blood neutrophil function in primary myelodysplastic syndrome. Br J Haematol 55:217–227

    PubMed  CAS  Google Scholar 

  129. Ruutu P (1986) Granulocyte function in myelodysplastic syndrome. Scand J Haematol 36(Suppl 45):66–70

    Google Scholar 

  130. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429–2440

    PubMed  CAS  Google Scholar 

  131. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA (2006) Further analysis of trials with azacytidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol 3895–3903

    Google Scholar 

  132. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR (2009) Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndrome: a randomized, open-label, phase III study. Lancet Oncol 10:223–232

    PubMed  CAS  Google Scholar 

  133. Personal communication, Dr. Kanti Rai. June 1998

    Google Scholar 

  134. Cheson BD (1995) Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431–2448

    PubMed  CAS  Google Scholar 

  135. Morrison VA, Rai KR, Peterson B et al (2001) Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study cancer and leukemia group B 9011. J Clin Oncol 19:3611–3621

    PubMed  CAS  Google Scholar 

  136. Anaissie EJ, Kontoyiannis DP, O’Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559–566

    PubMed  CAS  Google Scholar 

  137. Hensel M, Kornacker M, Yammeni S et al (2003) Disease activity and pretreatment, rather than hypogammaglobulinemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukemia. Br J Haematol 122:600–606

    PubMed  Google Scholar 

  138. Steurer M, Pall G, Richards S et al (2006) Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev 32:377–389

    PubMed  CAS  Google Scholar 

  139. Leporrier M, Chevret S, Cazin B et al (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319–2325

    PubMed  CAS  Google Scholar 

  140. Eichhorst BF, Busch R, Hopfinger G et al (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885–891

    PubMed  CAS  Google Scholar 

  141. O’Brien S, Moore JO, Boyd TE et al (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25:1114–1120

    PubMed  Google Scholar 

  142. Kowal M, Dmoszynska A, Lewandowski K et al (2004) Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL): polish multicentre study. Leuk Lymphoma 45:1159–1165

    PubMed  CAS  Google Scholar 

  143. Hainsworth JD, Litchy S, Barton JH et al (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746–1751

    PubMed  CAS  Google Scholar 

  144. Byrd JC, Peterson BL, Morrison VA et al (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood 101:6–14

    PubMed  CAS  Google Scholar 

  145. Keating MJ, O’Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079–4088

    PubMed  CAS  Google Scholar 

  146. Wierda W, O’Brien S, Wen S et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070–4078

    PubMed  CAS  Google Scholar 

  147. Robak T, Blonski JZ, Urbanska-Rys H, Blasinska-Morawiec M, Skotnicki AB (1999) 2-chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 13:518–523

    Google Scholar 

  148. Byrd JC, Peterson B, Piro L et al (2003) A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB study 9211. Leukemia 17:323–327

    PubMed  CAS  Google Scholar 

  149. Robak T, Blonski JZ, Kasznicki M et al (2000) Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia: updated results of the multicentre study of 378 patients. Br J Haematol 108:357–368

    PubMed  CAS  Google Scholar 

  150. Robak T, Blonski JZ, Kasznicki M et al (2000) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96:2723–2729

    PubMed  CAS  Google Scholar 

  151. Dillman RO, Mick R, McIntyre OR (1989) Pentostatin in chronic lymphocytic leukemia: a phase II trial of cancer and leukemia group B. J Clin Oncol 7:433–438

    PubMed  CAS  Google Scholar 

  152. Oken MM, Lee S, Kay NE et al (2004) Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 45:79–84

    PubMed  CAS  Google Scholar 

  153. Lamanna N, Kalaycio M, Maslak P et al (2006) Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575–1581

    PubMed  CAS  Google Scholar 

  154. Shanafelt TD, Lin T, Geyer SM et al (2007) Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109:2291–2298

    PubMed  CAS  Google Scholar 

  155. Keating MJ, Flinn I, Jain V et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554–3561

    PubMed  CAS  Google Scholar 

  156. Hillmen P, Skotnicki AB, Robak T et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616–5623

    PubMed  CAS  Google Scholar 

  157. Martin SI, Marty FM, Fiumara K et al (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43:16–24

    PubMed  CAS  Google Scholar 

  158. Elter T, Borchmann P, Schulz H et al (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23:7024–7031

    PubMed  CAS  Google Scholar 

  159. Faderl S, Thomas DA, O’Brien S et al (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413–3415

    PubMed  CAS  Google Scholar 

  160. O’Brien SM, Kantarjian HM, Thomas DA et al (2003) Alemtuzumab as treatment for residual diseased after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98:2657–2663

    PubMed  Google Scholar 

  161. Montillo M, Cafro AM, Tedeschi A et al (2002) Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 87:695–700

    PubMed  CAS  Google Scholar 

  162. Wendtner CM, Ritgen M, Schweighofer CD et al (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093–1101

    PubMed  CAS  Google Scholar 

  163. Rai KR, Byrd JC, Peterson BL, Larson RA (2002) A phase II trial of fludarabine followed by alemtuzumab in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: cancer and leukemia group B (CALGB) study 19901. Blood 100:205–206a

    Google Scholar 

  164. Rai KR, Byrd JC, Peterson BL et al (2003) Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901. Blood 102:676–677a

    Google Scholar 

  165. Morrison VA, Peterson BL, Rai KR et al (2007) Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: a comparative analysis of 3 cancer and leukemia group B studies (CALGB 9011, 9712, 19901). Blood 110:233a

    Google Scholar 

  166. Lin T, Donohue KA, Lucas MS et al (2007) Consolidation therapy with subcutaneous (SC) alemtuzumab results in serious infectious toxicity in previously untreated CLL patients who achieve a complete remission (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101. Blood 110:232–233a

    Google Scholar 

  167. Costa AJH, Costa DB, Shin B, Cooper DL (2004) Pneumococcemia as the presenting feature of multiple myeloma. Am J Heamtol 77:277–281

    Google Scholar 

  168. Perri RT, Hebbel R, Oken MM (1981) Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 71:935–938

    PubMed  CAS  Google Scholar 

  169. Rayner C, Haynes AP, Thompson JR et al (1991) Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q J Med 290:517–525

    Google Scholar 

  170. Savage DG, Lindenbaum J, Garrett TJ (1982) Biphasic pattern of bacterial infection in multiple myeloma. An Intern Med 96:47–50

    CAS  Google Scholar 

  171. Meyers BR, Hirschman SZ, Axelrod JA (1972) Current patterns of infection in multiple myeloma. Am J Med 52:87–92

    PubMed  CAS  Google Scholar 

  172. Espersen F, Birgens HS, Hertz JB et al (1984) Current patterns of infection in myelomatosis. Scan J Infect Dis 16:169–173

    CAS  Google Scholar 

  173. Shaikh BS, Lombard RM, Appelbaum PC et al (1982) Changing patterns of infection in patients with multiple myeloma. Oncology 39:78–82

    PubMed  CAS  Google Scholar 

  174. Twomey JT (1973) Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Int Med 132:562–565

    CAS  Google Scholar 

  175. Lortholary O, Ascioglu S, Moreau P et al (2000) Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer. Clin Infect Dis 30:41–46

    PubMed  CAS  Google Scholar 

  176. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487–2498

    PubMed  CAS  Google Scholar 

  177. Chanan-Khan A, Sonneveld P, Schuster MW et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26:4784–4790

    PubMed  CAS  Google Scholar 

  178. Kim SJ, Kim K, Kim BS et al (2008) Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymph Myeloma 8:237–240

    CAS  Google Scholar 

  179. Bennett C, Vardiman J, Golomb H (1986) Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 80:891–896

    PubMed  CAS  Google Scholar 

  180. Weinstein RA, Golomb HM, Grumet G, Gelmann E, Schechter GP (1981) Hairy cell leukemia: association with disseminated mycobacterial infection. Cancer 48:380–383

    PubMed  CAS  Google Scholar 

  181. Weinstein RA, Gelmann E, Golomb HM (1978) Disseminated atypical mycobacteria infection in hairy cell leukemia (letter). Lancet 2:1052

    PubMed  CAS  Google Scholar 

  182. Rice L, Shenkenberg T, Lynch C, Wheeler TM (1982) Granulomatous infections complicating hairy cell leukemia. Cancer 49:1924–1928

    PubMed  CAS  Google Scholar 

  183. Gallo JH, Young GAR, Forrest PR, Vincent PC, Jennis F (1983) Disseminated atypical mycobacteria infection in hairy cell leukemia. Pathology 15:241–245

    PubMed  CAS  Google Scholar 

  184. Weeks E, Jones CM, Guinee V (1992) Histoplasmosis in hairy cell leukemia: case report and review of the literature. Ann Hematol 65:138–142

    PubMed  CAS  Google Scholar 

  185. Audeh YM, Gruszecki AC, Cherrington A (2003) Hairy cell leukemia with concurrent cryptococcus infection. Am J Hematol 72:223–224

    PubMed  CAS  Google Scholar 

  186. Bennett CL, Westbrook CA, Gruber B (1986) Hairy cell leukemia and mucormycosis. Am J Med 81:1065–1067

    PubMed  CAS  Google Scholar 

  187. Ma B, Seymour JF, Januszewicz H (2001) Cure of pulmonary Rhizopus pusillis infection in a patient with hairy cell leukemia: role of liposomal amphotericin B and GM-CSF. Leuk Lymphoma 42:1393–1399

    PubMed  CAS  Google Scholar 

  188. Hoffman M (2006) Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clin North Am 20:1065–1073

    PubMed  Google Scholar 

  189. Edelman MJ, O’Donnell RT, Meadows I (1997) Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. Am J Hematol 54:329–331

    PubMed  CAS  Google Scholar 

  190. Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, Nakao S, Omine M, Ozawa K (2008) Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocytic leukemia-associated pure red cell aplasia: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 93:1555–1559

    PubMed  CAS  Google Scholar 

  191. Bartlett NL, Longo DL (1999) T-small lymphocytic disorders. Semin Hematol 36:164–170

    PubMed  CAS  Google Scholar 

  192. Weide R, Heymanns J, Koppler H, Tiemann M, Huss B, Pfluger KH, Havemann K (1994) Successful treatment of neutropenia in T-LGL leukemia (T gamma-lymphocytosis) with granulocyte colony stimulating factor. Ann Hamatol 69:117–119

    CAS  Google Scholar 

  193. Loughran TP (1993) Clonal diseases of large granular lymphocytes. Blood 82:1–14

    PubMed  Google Scholar 

  194. Loughran TP, Kidd PG, Starkebaum G (1994) Treatment of large granulocyte lymphocyte leukemia with oral low-dose methotrexate. Blood 84:2164–2170

    PubMed  Google Scholar 

  195. Casazza AR, Duvall CP, Carbone PP (1966) Infection in lymphoma: histology, treatment, and duration in relation to incidence and survival. JAMA 197:118–124

    Google Scholar 

  196. Casazza AR, Duvall CP, Carbone PP (1966) Summary of infectious complications occurring in patients with Hodgkin’s disease. Cancer Res 26:1290–1296

    PubMed  CAS  Google Scholar 

  197. Cohen S, Fisher B, Yoshida T (1974) Serum-migration inhibitory activity in patients with lymphoproliferative disease. N Engl J Med 290:882–886

    PubMed  CAS  Google Scholar 

  198. Aisenberg AC (1962) Studies on delayed hypersensitivity in Hodgkin’s disease. J Clin Invest 1964–1970

    Google Scholar 

  199. Gendel BR, Ende M, Norman SL (1950) Cryptococcosis: a review with special reference to apparent association with Hodgkin’s disease. Am J Med 9:343–355

    PubMed  CAS  Google Scholar 

  200. Hutter RVP, Collins HS (1962) The occurrence of opportunistic fungus infections in a cancer hospital. Lab Invest 11:1035–1045

    Google Scholar 

  201. Shanbrom E, Miller S, Haar H (1960) Herpes zoster in hematologic neoplasias: some unusual manifestations. Ann Intern Med 53:523–533

    PubMed  CAS  Google Scholar 

  202. Parker F, Jackson H, Bethea JM, Otis F (1932) Studies of diseases of lymphoid and myeloid tissues; coexistence of tuberculosis with Hodgkin’s disease and other forms of malignant lymphoma. Am J M Sci 184:694–699

    Google Scholar 

  203. Zimmerman LE, Rappaport H (1954) Occurrence of cryptococcosis in patients with malignant disease of reticuloendothelial system. Am J Clin Path 24:1050–1072

    PubMed  CAS  Google Scholar 

  204. Feldman S, Hughes WT, Daniel CB (1975) Varicella in children with cancer: seventy-seven cases. Pediatrics 56:388–397

    PubMed  CAS  Google Scholar 

  205. Arvin AM, Pollard RB, Rasmussen LE et al (1980) Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 68:869–878

    Google Scholar 

  206. Whitley RJ (1984) Varicella zoster infections. In: Galasso G, Merigan T, Buchanan R (eds) Antiviral agents and viral infections of man. Raven Press, New York, pp 517–541

    Google Scholar 

  207. Schimpff S, Serpick A, Stoler B et al (1972) Varicella-zoster infection in patients with cancer. Ann Intern Med 76:241–254

    PubMed  CAS  Google Scholar 

  208. Shambrom E, Miller S, Haar H (1960) Herpes zoster in hematologic neoplasias: some unusual manifestations. Ann Intern Med 53:523–533

    Google Scholar 

  209. Wright ET, Winer LH (1961) Herpes zoster and malignancy. Arch Dermat 84:242–247

    CAS  Google Scholar 

  210. Goffinet DR, Glatstein EJ, Merigan TC (1972) Herpes zoster—varicella infections and lymphoma. Ann Intern Med 76:235–240

    PubMed  CAS  Google Scholar 

  211. Mazur MH, Dolin R (1978) Herpes zoster at the NIH: a 20 year experience. Am J Med 65:738–744

    PubMed  CAS  Google Scholar 

  212. Arvin AM, Pollard RB, Rasmussen LE et al (1978) Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis 137:531–540

    PubMed  CAS  Google Scholar 

  213. Sokol SE, Firat D (1965) Varicella-zoster infection in Hodgkin’s disease. Am J Med 39:452–463

    Google Scholar 

  214. Guinee VF, Guido JJ, Pfalzgraf KA et al (1985) The incidence of herpes zoster in patients with Hodgkin’s disease: an analysis of prognostic factors. Cancer 56:642–647

    PubMed  CAS  Google Scholar 

  215. Ruckdeschel JC, Schimpff SC, Smyth AC et al (1977) Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin’s disease. Am J Med 62:77–85

    PubMed  CAS  Google Scholar 

  216. Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 319:902–907

    Google Scholar 

  217. Morrison VA, Byrd JC, Peterson BL et al (2003) Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: cancer and leukemia group B (CALGB) study [abstract]. Blood 102:440a

    Google Scholar 

  218. O’Brien S, Keating MJ, Mocarski ES (2006) Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7:125–130

    Google Scholar 

  219. Smith TF, Espy MJ, Mandrekar J et al (2007) Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis 45:1056–1061

    PubMed  CAS  Google Scholar 

  220. O’Brien S, Ravandi-Kashani F, Wierda WG et al (2005) A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. Blood 106:830a

    Google Scholar 

  221. Oken MM, Pomeroy C, Weisdorf D et al (1996) Prophylactic antibiotics for the prevention of infection in multiple myeloma. Am J Med 100:624–628

    PubMed  CAS  Google Scholar 

  222. Health and Public Policy Committee (1986) Position papers: pneumococcal vaccine. Ann Intern Med 104:118–120

    Google Scholar 

  223. Salmon SE, Samal BA, Hayes DM et al (1967) Role of gamma globulin for immunoprophylaxis in multiple myeloma. N Engl J Med 277:1336–1340

    PubMed  CAS  Google Scholar 

  224. Chapel HM, Lee M, Hargreaves R et al (1994) Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 343:1059–1063

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Sections of Hematology, Oncology, and Infectious Disease, University of Minnesota, VA Medical Center, One Veterans Dr, Minneapolis, MN, 55417, USA

    Vicki A. Morrison

Authors
  1. Vicki A. Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vicki A. Morrison .

Editor information

Editors and Affiliations

  1. Div. Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Valentina Stosor

  2. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Teresa R. Zembower

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland (outside USA)

About this chapter

Cite this chapter

Morrison, V.A. (2014). Infections in Patients with Leukemia and Lymphoma. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Cham. https://doi.org/10.1007/978-3-319-04220-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-04220-6_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-04219-0

  • Online ISBN: 978-3-319-04220-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation